Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies. Reach her on Signal at margaretmanto.61.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we discuss the first gene therapy approval for Sanfilippo syndrome, learn of a rare gene variant linked to dramatically heightened lung cancer risk in non-smokers, and look ahead toward the confirmation hearing for the nominee to lead the FDA.

About the Sanfilipo approval: I first wrote about the effort to develop a therapy a decade ago. I get melancholy sometimes when I think of how many kids have declined or died before their families can get cutting-edge therapies approved for children who are not their own. But science takes time, and biotech can produce a better tomorrow, no?

1. 

   Biotech Correspondent

   Meghana Keshavan covers biotech and contributes to The Readout newsletter.

2. 

   Senior Writer, Biotech

   Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

3. 

   Washington Correspondent

   Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies. Reach her on Signal at margaretmanto.61.